MX2018002255A - Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa. - Google Patents
Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa.Info
- Publication number
- MX2018002255A MX2018002255A MX2018002255A MX2018002255A MX2018002255A MX 2018002255 A MX2018002255 A MX 2018002255A MX 2018002255 A MX2018002255 A MX 2018002255A MX 2018002255 A MX2018002255 A MX 2018002255A MX 2018002255 A MX2018002255 A MX 2018002255A
- Authority
- MX
- Mexico
- Prior art keywords
- oxime derivative
- levodopa
- therapy
- penetrant
- brain
- Prior art date
Links
- IPDGWIYTNQXKSP-UHFFFAOYSA-N n-chromen-4-ylidenehydroxylamine Chemical class C1=CC=C2C(=NO)C=COC2=C1 IPDGWIYTNQXKSP-UHFFFAOYSA-N 0.000 title abstract 3
- 208000012661 Dyskinesia Diseases 0.000 title abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004502 levodopa Drugs 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un derivado de oxima de cromona de la fórmula (I), que es un modulador de los receptores del sistema nervioso sensibles al glutamato de aminoácido neuroexcitatorio y presenta una exposición cerebral convenientemente alta con la administración oral, para el tratamiento o prevención de disquinesia inducida por levodopa. La presente invención también proporciona una terapia mejorada de la enfermedad de Parkinson, utilizando el derivado de oxima de cromona de la fórmula (I) en combinación con levodopa. (ver fórmula I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/069601 WO2016030444A1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| EP15188368 | 2015-10-05 | ||
| PCT/EP2016/070175 WO2017032874A1 (en) | 2015-08-27 | 2016-08-26 | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018002255A true MX2018002255A (es) | 2018-06-06 |
Family
ID=54260666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002255A MX2018002255A (es) | 2015-08-27 | 2016-08-26 | Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10532057B2 (es) |
| EP (2) | EP3341380B1 (es) |
| JP (1) | JP2018528205A (es) |
| KR (1) | KR20180041234A (es) |
| CN (1) | CN108349993A (es) |
| AU (1) | AU2016313138A1 (es) |
| CA (1) | CA2995313A1 (es) |
| CL (1) | CL2018000497A1 (es) |
| CY (1) | CY1122401T1 (es) |
| DK (1) | DK3341380T3 (es) |
| DO (1) | DOP2018000060A (es) |
| EA (1) | EA035016B1 (es) |
| ES (1) | ES2764490T3 (es) |
| HR (1) | HRP20192250T1 (es) |
| HU (1) | HUE047531T2 (es) |
| IL (1) | IL257655A (es) |
| LT (1) | LT3341380T (es) |
| MA (1) | MA42700B1 (es) |
| ME (1) | ME03591B (es) |
| MX (1) | MX2018002255A (es) |
| NI (1) | NI201800031A (es) |
| PH (1) | PH12018500430A1 (es) |
| PL (1) | PL3341380T3 (es) |
| PT (1) | PT3341380T (es) |
| RS (1) | RS59651B1 (es) |
| RU (1) | RU2018110580A (es) |
| SI (1) | SI3341380T1 (es) |
| SM (1) | SMT201900720T1 (es) |
| TN (1) | TN2018000061A1 (es) |
| WO (1) | WO2017032874A1 (es) |
| ZA (1) | ZA201801642B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58592B1 (sr) * | 2014-08-27 | 2019-05-31 | Prexton Therapeutics Sa | Novi derivat hromon oksima i njegova upotreba kao alosterni modulator metabotropnih glutamatnih receptora |
| RS59651B1 (sr) | 2015-08-27 | 2020-01-31 | Prexton Therapeutics Sa | Derivat hromonoksima koji prodire u mozak u svrhu terapije diskinezije uzrokovane levodopom |
| JP7633676B2 (ja) | 2018-07-26 | 2025-02-20 | ドメイン・セラピューティクス | 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用 |
| EP3807077A4 (en) | 2018-12-14 | 2021-12-29 | Hewlett-Packard Development Company, L.P. | Evaluating candidate virtual build volumes |
| GB202016425D0 (en) * | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| CN115594655B (zh) * | 2022-09-16 | 2023-08-15 | 桂林医学院 | 色酮肟类衍生物及其制备方法和应用 |
| WO2024117683A1 (ko) * | 2022-11-30 | 2024-06-06 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| JP3993651B2 (ja) | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004092154A1 (en) * | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| WO2007011701A1 (en) | 2005-07-15 | 2007-01-25 | Transform Pharmaceuticals, Inc. | Novel hydrochloride salts of levodopa |
| CA2696016A1 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| US8962627B2 (en) | 2009-10-30 | 2015-02-24 | Prestwick Chemical, Inc. | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| MX388468B (es) | 2009-12-04 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Compuestos multicíclicos y métodos de uso de los mismos. |
| JP5774610B2 (ja) * | 2010-03-04 | 2015-09-09 | オリオン コーポレーション | パーキンソン病の治療方法 |
| RS58592B1 (sr) | 2014-08-27 | 2019-05-31 | Prexton Therapeutics Sa | Novi derivat hromon oksima i njegova upotreba kao alosterni modulator metabotropnih glutamatnih receptora |
| RS59651B1 (sr) | 2015-08-27 | 2020-01-31 | Prexton Therapeutics Sa | Derivat hromonoksima koji prodire u mozak u svrhu terapije diskinezije uzrokovane levodopom |
-
2016
- 2016-08-26 RS RS20191571A patent/RS59651B1/sr unknown
- 2016-08-26 EA EA201890590A patent/EA035016B1/ru not_active IP Right Cessation
- 2016-08-26 PL PL16769872T patent/PL3341380T3/pl unknown
- 2016-08-26 CA CA2995313A patent/CA2995313A1/en not_active Abandoned
- 2016-08-26 RU RU2018110580A patent/RU2018110580A/ru not_active Application Discontinuation
- 2016-08-26 HR HRP20192250TT patent/HRP20192250T1/hr unknown
- 2016-08-26 HU HUE16769872A patent/HUE047531T2/hu unknown
- 2016-08-26 EP EP16769872.9A patent/EP3341380B1/en active Active
- 2016-08-26 SI SI201630559T patent/SI3341380T1/sl unknown
- 2016-08-26 AU AU2016313138A patent/AU2016313138A1/en not_active Abandoned
- 2016-08-26 WO PCT/EP2016/070175 patent/WO2017032874A1/en not_active Ceased
- 2016-08-26 CN CN201680062784.8A patent/CN108349993A/zh active Pending
- 2016-08-26 PT PT167698729T patent/PT3341380T/pt unknown
- 2016-08-26 DK DK16769872.9T patent/DK3341380T3/da active
- 2016-08-26 JP JP2018510876A patent/JP2018528205A/ja active Pending
- 2016-08-26 ES ES16769872T patent/ES2764490T3/es active Active
- 2016-08-26 SM SM20190720T patent/SMT201900720T1/it unknown
- 2016-08-26 LT LTEP16769872.9T patent/LT3341380T/lt unknown
- 2016-08-26 US US15/755,435 patent/US10532057B2/en not_active Expired - Fee Related
- 2016-08-26 KR KR1020187008542A patent/KR20180041234A/ko not_active Withdrawn
- 2016-08-26 EP EP19207959.8A patent/EP3696182A1/en not_active Withdrawn
- 2016-08-26 MA MA42700A patent/MA42700B1/fr unknown
- 2016-08-26 MX MX2018002255A patent/MX2018002255A/es unknown
- 2016-08-26 ME MEP-2019-346A patent/ME03591B/me unknown
- 2016-08-26 TN TNP/2018/000061A patent/TN2018000061A1/en unknown
-
2018
- 2018-02-21 IL IL257655A patent/IL257655A/en unknown
- 2018-02-23 CL CL2018000497A patent/CL2018000497A1/es unknown
- 2018-02-23 NI NI201800031A patent/NI201800031A/es unknown
- 2018-02-26 DO DO2018000060A patent/DOP2018000060A/es unknown
- 2018-02-27 PH PH12018500430A patent/PH12018500430A1/en unknown
- 2018-03-09 ZA ZA2018/01642A patent/ZA201801642B/en unknown
-
2019
- 2019-12-10 CY CY20191101297T patent/CY1122401T1/el unknown
- 2019-12-11 US US16/709,988 patent/US20200171042A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500430A1 (en) | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia | |
| CL2019001685A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. | |
| MX2019014974A (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| PH12013501389A1 (en) | Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy | |
| PH12017500746B1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| MY190408A (en) | Compositions and methods for treating cns disorders | |
| MX388470B (es) | Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados. | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| MX377438B (es) | Administracion de tasimelteon en condiciones de ayuno. | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| MX2018005756A (es) | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| NZ728853A (en) | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | |
| MX2016013741A (es) | Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. | |
| MX2021003204A (es) | Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo. | |
| BR112019002799A8 (pt) | Composto, composição farmacêutica, método para tratar um indivíduo tendo uma doença neurodegenerativa, método para tratar um indivíduo tendo a doença de alzheimer e método para tratar um indivíduo tendo uma doença ou condição | |
| MX2018002786A (es) | Composicion farmaceutica de vinpocetina. | |
| UA91605U (uk) | Спосіб корекції порушень мікроциркуляції в слизовій оболонці шлунка у людей літнього віку |